Hansoh Pharmaceutical Group Company Limited
3692
Clasificación en acciones
#903
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Precio por acción
$4.38
Capitalización bursátil
$26.56B
Cambio (1 día)
-0.38%
Cambio (1 año)
-5.15%
País
CN
Comercio Hansoh Pharmaceutical Group Company Limited (3692)
Categoría
Healthcare
Ingresos de Hansoh Pharmaceutical Group Company Limited (3692)
Ingresos en Jun 2026 TTM: $2.30B
Según los últimos informes financieros de Hansoh Pharmaceutical Group Company Limited, los ingresos actuales de la empresa (TTM) son $2.30B. En 2023, la empresa obtuvo unos ingresos de $1.43B un aumento con respecto a los ingresos del año 2022, que fueron de $1.36B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Hansoh Pharmaceutical Group Company Limited desde 2016 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $2.30B | 37.16% |
| 2024 | $1.68B | 17.68% |
| 2023 | $1.43B | 4.94% |
| 2022 | $1.36B | -12.98% |
| 2021 | $1.56B | 17.51% |
| 2020 | $1.33B | 6.68% |
| 2019 | $1.25B | 11.07% |
| 2018 | $1.12B | 18.09% |
| 2017 | $950.71M | 21.49% |
| 2016 | $782.52M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 186.97% |
IN
|
